These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33159495)

  • 21. Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
    Quiles F; Menéndez M; Tornero E; del Valle J; Teulé À; Palanca S; Izquierdo A; Gómez C; Campos O; Santamaria R; Brunet J; Capellá G; Feliubadaló L; Lázaro C
    Breast Cancer Res Treat; 2016 Jan; 155(2):253-60. PubMed ID: 26780556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and Characterization of a New BRCA2 Rearrangement in an Italian Family with Hereditary Breast and Ovarian Cancer Syndrome.
    Concolino P; Rizza R; Hackmann K; Minucci A; Scaglione GL; De Bonis M; Costella A; Zuppi C; Schrock E; Capoluongo E
    Mol Diagn Ther; 2017 Oct; 21(5):539-545. PubMed ID: 28620890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From a variant of unknown significance to pathogenic: Reclassification of a large novel duplication in BRCA2 by high-throughput sequencing.
    van Luttikhuizen JL; Bublitz J; Schubert S; Schmidt G; Hofmann W; Morlot S; Buurman R; Auber B; Schlegelberger B; Steinemann D
    Mol Genet Genomic Med; 2020 Sep; 8(9):e1045. PubMed ID: 31724318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
    BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
    Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
    Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.
    Baert A; Machackova E; Coene I; Cremin C; Turner K; Portigal-Todd C; Asrat MJ; Nuk J; Mindlin A; Young S; MacMillan A; Van Maerken T; Trbusek M; McKinnon W; Wood ME; Foulkes WD; Santamariña M; de la Hoya M; Foretova L; Poppe B; Vral A; Rosseel T; De Leeneer K; Vega A; Claes KBM
    Hum Mutat; 2018 Apr; 39(4):515-526. PubMed ID: 29280214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.
    Pinheiro M; Peixoto A; Santos C; Escudeiro C; Bizarro S; Pinto P; Santos R; Pinto C; Guerra J; Silva J; Teixeira MR
    Cancer Genet; 2020 Oct; 248-249():18-24. PubMed ID: 32971473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
    Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S;
    Jpn J Clin Oncol; 2020 Dec; 50(12):1380-1385. PubMed ID: 32676635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
    Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
    Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a Splice Variant (c.5074+3A>C) of
    Hong J; Kim JH; Ahn SH; Gu H; Chang S; Lee W; Kim DY; Chun S; Min WK
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
    Montalban G; Bonache S; Moles-Fernández A; Gadea N; Tenés A; Torres-Esquius S; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
    Hum Mutat; 2019 Dec; 40(12):2296-2317. PubMed ID: 31343793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.
    Pajares B; Porta J; Porta JM; Sousa CF; Moreno I; Porta D; Durán G; Vega T; Ortiz I; Muriel C; Alba E; Márquez A
    BMC Cancer; 2018 Jun; 18(1):647. PubMed ID: 29884136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
    Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
    Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
    Zhang L; Bacares R; Boyar S; Hudis C; Nafa K; Offit K
    Mutat Res; 2009 Apr; 663(1-2):84-9. PubMed ID: 19070627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known BRCA Mutations.
    Caminsky NG; Mucaki EJ; Perri AM; Lu R; Knoll JH; Rogan PK
    Hum Mutat; 2016 Jul; 37(7):640-52. PubMed ID: 26898890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel de novo BRCA2 mutation in a patient with a family history of breast cancer.
    Hansen TV; Bisgaard ML; Jønson L; Albrechtsen A; Filtenborg-Barnkob B; Eiberg H; Ejlertsen B; Nielsen FC
    BMC Med Genet; 2008 Jul; 9():58. PubMed ID: 18597679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
    Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
    Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA2 c.8827C>T pathogenic mutation in a consanguineous Chinese family with hereditary breast cancer.
    Wang J; Qin J; Xi C; Zhang Y
    Mol Genet Genomic Med; 2020 Sep; 8(9):e1411. PubMed ID: 32686918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.